STAT+: Amylyx nears pivotal endocrine drug study readout

STAT PlusOpinionAdam’s Biotech Scorecard Amylyx nears pivotal endocrine drug study readout Plus: Biogen, investors at odds over Alzheimer’s drug future Manage alerts for this article Email this article Share this article By Adam FeuersteinJuly 16, 2026 Senior Writer, Biotech Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Later this quarter, Amylyx Pharmaceuticals will read out results from a study evaluating a new treatment for a rare endocrine disorder. It’s a pivotal moment that could support the drug’s approval and comes two years after Amylyx was rocked — and lauded — for voluntarily pulling a drug for ALS off the market because a follow-on study showed it wasn’t helping patients.Advertisement The Amylyx drug, avexitide, is being developed to halt severe, uncontrolled drops in blood sugar that some people experience after undergoing stomach-reducing surgery for weight loss. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Alzheimer’s, biotechnology, chronic diseases, drug development, Pharmaceuticals, rare diseases, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Adam's Biotech Scorecard July 9, 2026 STAT Plus: 931 days. The drug approval scandal hiding in plain sight Adam's Biotech Scorecard July 2, 2026 STAT Plus: Halfway into the year, biotech is booming Advertisement Adam's Biotech Scorecard June 18, 2026 STAT Plus: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept Adam's Biotech Scorecard June 11, 2026 STAT Plus: ‘Synthetic lethality’ could trigger another round of biotech M&A Adam's Biotech Scorecard June 4, 2026 STAT Plus: Does Revolution Medicines’ pancreatic cancer drug have even greater potential? Subscriber Picks